NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
Section snippets
Name and Family History
The etymology of NY‐ESO‐1 tells the story of its origins: NY stands for the city in which it was discovered by Chen et al. (1997), at the Ludwig Institute for Cancer Research and Weill Medical College of Cornell University in New York, in 1997; ESO is for esophageal cancer where it was originally described by screening a tumor‐derived cDNA expression library with autologous serum of an esophageal cancer patient; and this was the first member of a new gene family.
The gene coding for NY‐ESO‐1,
Indications and Usage: Expression of NY‐ESO‐1 in Tumor Cells
The promise of NY‐ESO‐1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal tissues but frequent occurrence in cancer. Although originally described from the cDNA sequences of an esophageal tumor, NY‐ESO‐1 has shown a much more widespread incidence in a number of other tumor types. The expression of NY‐ESO‐1 has been analyzed in surgically removed primary or metastatic cancer tissues on two levels: message by RT‐PCR and protein by
Concluding Remarks
Knowing what to expect is not a luxury when planning immunotherapeutic intervention, and NY‐ESO‐1 with its strong inherent immunogenicity in a subset of cancer patients has set the standards to reach. With a booming number of clinical trials with NY‐ESO‐1 as a model antigen, clinical correlations of immunogenicity and patient benefit, if any, should soon be established. Current vaccines still have a lot of room for improvement, both in antigen and in adjuvant formulations. An efficient vaccine
Acknowledgments
We are grateful to Ramon Chua and Bernadette Keitz for their help in generating and compiling the RT‐PCR data.
Financial Support: Supported by the Cancer Vaccine Collaborative funded by the Cancer Research Institute and Ludwig Institute for Cancer Research.
References (109)
- et al.
A new member of the NY‐ESO‐1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved
Gene
(2002) - et al.
Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC
J. Immunol. Methods
(2003) - et al.
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling
Cell
(2005) - et al.
Cancer/testis tumour‐associated antigens: Immunohistochemical detection with monoclonal antibodies
Lancet Oncol.
(2003) - et al.
CD4+ CD25+ regulatory T cells control the induction of antigen‐specific CD4+ helper T cell responses in cancer patients
Blood
(2005) - et al.
hMAGE‐A1 overexpression reduces TNF‐alpha cytotoxicity in ME‐180 cells
Mol. Cells
(2002) - et al.
Expression of cancer/testis (CT) antigens in chinese hepatocellular carcinoma and its correlation with clinical parameters
Cancer Lett.
(2005) - et al.
The cancer‐testis gene, NY‐ESO‐1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ
Lab. Invest.
(2002) - et al.
Expression of cancer/testis (CT) antigens in lung cancer
Lung Cancer
(2003) - et al.
NY‐ESO‐1 is highly expressed in poor‐prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
Blood
(2005)